QPS expands its product offering with robust pharmacological disease models, including steatohepatitis associated with metabolic dysfunction, ulcerative colitis, wound healing, and psoriasis.

TAIPEI, Taiwan--(BUSINESS WIRE)--Apr. 23, 2025-

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis

HANGZHOU, China, April 22, 2025 /PRNewswire/ — Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), and Glucagon-like peptide-1 receptor (GLP-1R) has completed the dosing of […]